We have recently developed the Prediction of MLH1 and MSH2 mutations model (PREMM1,2), a clinical prediction rule designed to be used by healthcare providers to estimate the probability that an individual carries a mutation in the MLH1 or MSH2 mismatch repair genes (Balmana et al. JAMA 2006). PREMM1,2 was developed and subsequently validated in over 2000 patients who were at elevated risk of Lynch Syndrome and undergoing genetic evaluation. Lynch Syndrome, also known as hereditary non- polyposis colorectal cancer (HNPCC), is the most common hereditary colon cancer syndrome, and also increases the risk for several extracolonic cancers. MLH1 and MSH2 mutations are the most common underlying cause. In a subset of families, mutations are found in a third mismatch repair gene, MSH6, and lead to a milder phenotype. Tumors in patients with Lynch syndrome demonstrate microsatellite instability (MSI) and can show loss of expression of the affected mismatch repair gene, which may be detected by immunohistochemical analysis (IHC). In addition to PREMM1,2, two other prediction models have recently been developed, and a variety of clinical guidelines are also available for the clinician as risk assessment tools. The performance characteristics of the available models and clinical guidelines have not been compared with another, nor is it known which approach, or combination of approaches, is the most cost-effective method of identifying and managing patients with Lynch Syndrome. As an expansion of our prior work, the aims of this project are (1) To validate PREMM1,2 in several existing U.S. and international colon cancer registries, including the Colon Cancer Family Registries (CCFR), EPICOLON, and Ohio State cohorts;(2)To expand the PREMM1, 2 model to include prediction of MSH6 mutation carriers;(3) To develop a version of the PREMMM1,2,6 model that (i) allows for the incorporation of information on MSI and IHC for further refinement of the predicted probabilities of a germline mutation, and (ii) makes gene-specific predictions based on clinical history, MSI and IHC results;(4)To compare the PREMMM1,2,6 , Barnetson, MMRPro models in (i) their ability to distinguish mutation carriers from non-carriers;(ii) different settings (population or clinic-based cases);(iii) a population-based series of endometrial cancer cases;and (5) To perform a cost-effectiveness analysis to define the role of the PREMM1,2,6 model and other clinical and molecular strategies for identification of individuals at risk of Lynch syndrome.

Public Health Relevance

The results of this effort will achieve several goals of PA-07-021. It will (i) lead to a comprehensive clinical and public health approach to the identification and management of patients with hereditary colon cancer;(ii) allow for more precise estimation of the specific tumors associated with each MMR gene and therefore more targeted cancer screening and prevention approaches;and (iii) bring together investigators from diverse backgrounds, including geneticists, molecular epidemiologists, statisticians and clinicians, who will work together, share existing data and expertise to address research questions that could not be answered in isolation.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Epidemiology of Cancer Study Section (EPIC)
Program Officer
Freedman, Andrew
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772
Canto, Marcia Irene; Almario, Jose Alejandro; Schulick, Richard D et al. (2018) Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 155:740-751.e2
Luba, Daniel G; DiSario, James A; Rock, Colleen et al. (2018) Community Practice Implementation of a Self-administered Version of PREMM1,2,6 to Assess Risk for Lynch Syndrome. Clin Gastroenterol Hepatol 16:49-58
Kastrinos, Fay; Uno, Hajime; Ukaegbu, Chinedu et al. (2017) Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol 35:2165-2172
Yurgelun, Matthew B; Kulke, Matthew H; Fuchs, Charles S et al. (2017) Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol 35:1086-1095
Kastrinos, Fay; Ojha, Rohit P; Leenen, Celine et al. (2016) Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer. J Natl Cancer Inst 108:
Inra, Jennifer A; Steyerberg, Ewout W; Grover, Shilpa et al. (2015) Racial variation in frequency and phenotypes of APC and MUTYH mutations in 6,169 individuals undergoing genetic testing. Genet Med 17:815-21
Yurgelun, Matthew B; Allen, Brian; Kaldate, Rajesh R et al. (2015) Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Gastroenterology 149:604-13.e20
Kastrinos, Fay; Steyerberg, Ewout W (2015) Family matters in lynch syndrome. J Natl Cancer Inst 107:
Everett, Jessica N; Raymond, Victoria M; Dandapani, Monica et al. (2014) Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm. JAMA Dermatol 150:1315-21

Showing the most recent 10 out of 14 publications